Complete remission of metastatic renal cell carcinoma to the bone with sunitinib

Akihiro Yoshimura; Wataru Nakata; Gaku Yamamichi; Go Tsujimura; Yuichi Tsujimoto; Mikio Nin; Masao Tsujihata

doi:10.1016/j.eucr.2020.101213

Complete remission of metastatic renal cell carcinoma to the bone with sunitinib

Urol Case Rep. 2020 Apr 17:32:101213. doi: 10.1016/j.eucr.2020.101213. eCollection 2020 Sep.

Authors

Akihiro Yoshimura¹, Wataru Nakata¹, Gaku Yamamichi¹, Go Tsujimura¹, Yuichi Tsujimoto¹, Mikio Nin¹, Masao Tsujihata¹

Affiliation

¹ Departments of Urology, Osaka Rosai Hospital, 1179-3 Nagasone, Kitaku, Sakai City, Osaka, 591-8025, Japan.

Abstract

Target agents such as tyrosine kinase inhibitors have improved renal cell carcinoma (RCC) patient outcomes. However, complete remission (CR) with target agents is rare. Furthermore, CR of bone metastasis is much less common. We report a case of CR in bone and lung metastatic RCC. Radical nephrectomy was performed first, and clear cell RCC was diagnosed. Thereafter, sunitinib was started, and bone and lung metastases resolved entirely after 8 months of treatment. Sunitinib therapy was discontinued after 2 years because of the adverse event of proteinuria. However, the patient has remained in CR for over 1 year after sunitinib cessation.

Keywords: Bone metastasis; Complete response; Renal cell carcinoma; Sunitinib.

Publication types

Case Reports